MARKET

ICCC

ICCC

ImmuCell
NASDAQ

Real-time Quotes | Nasdaq Last Sale

9.76
-0.08
-0.76%
Closed 16:00 09/23 EDT
OPEN
9.66
PREV CLOSE
9.83
HIGH
9.95
LOW
9.62
VOLUME
3.21K
TURNOVER
--
52 WEEK HIGH
13.20
52 WEEK LOW
5.01
MARKET CAP
75.52M
P/E (TTM)
-158.3604
1D
5D
1M
3M
1Y
5Y
Is ImmuCell (NASDAQ:ICCC) Weighed On By Its Debt Load?
The external fund manager backed by Berkshire Hathaway's Charlie Munger, Li Lu, makes no bones about it when he says...
Simply Wall St. · 09/08 12:55
60 Biggest Movers From Yesterday
Gainers
Benzinga · 08/25 08:50
Mid-Afternoon Market Update: Nasdaq Rises 75 Points; Palo Alto Networks Shares Jump On Upbeat Earnings
Toward the end of trading Tuesday, the Dow traded up 0.26% to 35,427.95 while the NASDAQ rose 0.50% to 15,018.26. The S&P also rose, gaining 0.25% to 4,490.82.
Benzinga · 08/24 18:45
EDU, SESN and GOTU among mid-day movers
Gainers: Takung Art (NYSE:TKAT) +48%. Triple-S Management (NYSE:GTS) +45%. KLX Energy (NASDAQ:KLXE) +25%. New Oriental Education (NYSE:EDU) +26%. SkyWater Technology (NASDAQ:SKYT) +25%. Sentage (NASDAQ:SNTG) +24%. Bio-Path Holdings (NASDAQ:BPTH) +20%. TuSi...
Seekingalpha · 08/24 16:34
Mid-Day Market Update: Crude Oil Rises Over 2%; Theravance Biopharma Shares Slide
Midway through trading Tuesday, the Dow traded up 0.09% to 35,368.20 while the NASDAQ rose 0.40% to 15,001.95. The S&P also rose, gaining 0.14% to 4,486.01.
Benzinga · 08/24 16:17
Sector Update: Health Care
MT Newswires · 08/24 15:52
Triple-S Management, Bio-Path leads healthcare gainers; Theravance Biopharma, Vivos Therapeutics among major losers
Gainers: Triple-S Management (NYSE:GTS) +45%, Bio-Path (NASDAQ:BPTH) +21%, Reviva Pharmaceuticals (NASDAQ:RVPH) +21%, XTL Biopharmaceuticals (NASDAQ:XTLB) +13%, Protara Therapeutics (NASDAQ:TARA) +12%. Losers: Theravance Biopharma (NASDAQ:TBPH) -31%, Vivos...
Seekingalpha · 08/24 15:10
BRIEF-Immucell Corp Says Required To Prepare Second Submission Of Final Major Technical Section For Re-Tain
reuters.com · 08/24 14:15
More
Forecast
Actual (USD)
Estimate (USD)
Income StatementMore
Net Income (USD)
YoY (%)
Balance SheetMore
Total Assets (USD)
Total Liabilities (USD)
Debt to Asset (%)
Cash FlowMore
Operating (USD)
YoY (%)
Learn about the latest financial forecast of ICCC. Analyze the recent business situations of ImmuCell through EPS, BVPS, FPS, and other data. This information may help you make smarter investment decisions.
Analyst Rating

Based on 1 analysts

Buy

Disclaimer: The analysis information is for reference only and does not constitute an investment recommendation.

Analyst Price Target
The average ICCC stock price target is 14.00 with a high estimate of 14.00 and a low estimate of 14.00.
EPS
Institutional Holdings
Institutions: 36
Institutional Holdings: 1.19M
% Owned: 15.41%
Shares Outstanding: 7.74M
TypeInstitutionsShares
Increased
5
20.92K
New
1
60.61K
Decreased
7
23.36K
Sold Out
1
20.38K
  • Performance
  • Asset Allocation
  • Dividend History
No Data
Industry
Biotechnology & Medical Research
+1.87%
Pharmaceuticals & Medical Research
+1.27%
Key Executives
Chairman/Director
David Tomsche
President/Chief Executive Officer/Treasurer/Secretary/Director
Michael Brigham
Chief Scientific Officer/Vice President
Joseph Crabb
Vice President/Director of Sales/Director of Marketing/Director
Bobbi Brockmann
Vice President
Elizabeth Williams
Independent Director
Gloria Basse
Independent Director
David Cunningham
Independent Director
Steven Rosgen
Independent Director
Jonathan Rothschild
Independent Director
Paul Wainman
No Data
About ICCC
ImmuCell Corporation is an animal health company. The Company is engaged in development, acquisition, manufacture and sale of products that improve the health and productivity of dairy and beef cattle. It manufactures and markets the First Defense product line for the prevention of scours in newborn dairy and beef calves. It expanded this line into five different products with formulations targeting E. coli and coronavirus pathogens as well as E. coli, coronavirus and rotavirus pathogens. Its Tri-Shield First Defense product line extension is calf-level, passive antibody product providing immediate immunity against E. coli, coronavirus and rotavirus. These product line provides Immediate Immunity to newborn calves. The Company is engaged in development of Re-Tain, a Nisin treatment for subclinical mastitis in lactating dairy cows. Its products reduce the use of traditional antibiotics in food producing animals.

Webull offers kinds of ImmuCell Corporation stock information, including NASDAQ:ICCC real-time market quotes, financial reports, professional analyst ratings, in-depth charts, corporate actions, ICCC stock news, and many more online research tools to help you make informed decisions.

You can practice and explore trading ICCC stock methods without spending real money on the virtual paper trading platform.